SG11201902988UA - Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof - Google Patents

Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Info

Publication number
SG11201902988UA
SG11201902988UA SG11201902988UA SG11201902988UA SG11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA SG 11201902988U A SG11201902988U A SG 11201902988UA
Authority
SG
Singapore
Prior art keywords
compositions
international
methods
novel
pct
Prior art date
Application number
SG11201902988UA
Other languages
English (en)
Inventor
Frank Bedu-Addo
Greg Conn
Martin Ward
Jerold Woodward
Original Assignee
Pds Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pds Biotechnology Corp filed Critical Pds Biotechnology Corp
Publication of SG11201902988UA publication Critical patent/SG11201902988UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11201902988UA 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof SG11201902988UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404458P 2016-10-05 2016-10-05
PCT/US2017/055119 WO2018067689A1 (en) 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201902988UA true SG11201902988UA (en) 2019-05-30

Family

ID=61757761

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201902988UA SG11201902988UA (en) 2016-10-05 2017-10-04 Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof

Country Status (12)

Country Link
US (2) US11401306B2 (ja)
EP (1) EP3522908A4 (ja)
JP (3) JP7165652B2 (ja)
KR (1) KR20190073416A (ja)
CN (1) CN110035765B (ja)
AU (2) AU2017340407A1 (ja)
BR (1) BR112019006831A2 (ja)
CA (1) CA3039211A1 (ja)
IL (1) IL265833A (ja)
MX (1) MX2019003961A (ja)
SG (1) SG11201902988UA (ja)
WO (1) WO2018067689A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP2015530413A (ja) 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2021505606A (ja) * 2017-12-05 2021-02-18 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｉ型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物
US20220062397A1 (en) * 2019-01-03 2022-03-03 Evaxion Biotech Aps Vaccines targeting neoepitopes
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
WO2024086169A2 (en) * 2022-10-17 2024-04-25 Pds Biotechnology Corporation Novel non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancers
WO2024086290A2 (en) * 2022-10-19 2024-04-25 Pds Biotechnology Corporation Novel t cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
AU785319B2 (en) * 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP2009534332A (ja) * 2006-04-21 2009-09-24 トランジェーヌ、ソシエテ、アノニム パピローマウイルスワクチン
CN105031610B (zh) * 2007-05-31 2020-06-19 莱顿教学医院 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位
US9539320B2 (en) 2009-05-15 2017-01-10 Irx Therapeutics, Inc. Vaccine immunotherapy
CN110075292A (zh) * 2011-09-12 2019-08-02 Pds生物科技公司 微粒疫苗制剂
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
JP2015530413A (ja) * 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
ES2693213T3 (es) 2013-10-23 2018-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epítopos agonistas de HLA-A24 de oncoproteína MUC1-C y composiciones y métodos de uso
CA2979493A1 (en) * 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Also Published As

Publication number Publication date
AU2017340407A1 (en) 2019-05-02
BR112019006831A2 (pt) 2019-07-30
MX2019003961A (es) 2019-08-26
JP7397945B2 (ja) 2023-12-13
JP2019533658A (ja) 2019-11-21
JP2022191472A (ja) 2022-12-27
JP2024023507A (ja) 2024-02-21
AU2021200200B2 (en) 2024-07-11
CA3039211A1 (en) 2018-04-12
WO2018067689A1 (en) 2018-04-12
JP7165652B2 (ja) 2022-11-04
CN110035765A (zh) 2019-07-19
US11401306B2 (en) 2022-08-02
EP3522908A1 (en) 2019-08-14
KR20190073416A (ko) 2019-06-26
AU2021200200A1 (en) 2021-03-18
CN110035765B (zh) 2024-04-02
IL265833A (en) 2019-06-30
US20220332768A1 (en) 2022-10-20
US20180094032A1 (en) 2018-04-05
EP3522908A4 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201803906PA (en) Control of cellular redox levels
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811432WA (en) Rna for cancer therapy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909311TA (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201909584QA (en) Triterpene saponin analogues
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901347UA (en) Compositions and methods for cancer immunotherapy